Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years

Abstract Purpose To examine the potential relationship between androgen deprivation therapy and other-cause mortality (OCM) in patients with prostate cancer treated with medical primary-androgen deprivation therapy, prostatectomy, or radiation. Methods A total of 137,524 patients with non-metastatic...

Full description

Saved in:
Bibliographic Details
Published in:European journal of surgical oncology 2015-11, Vol.41 (11), p.1529-1539
Main Authors: Abdollah, F, Sammon, J.D, Reznor, G, Sood, A, Schmid, M, Klett, D.E, Sun, M, Aizer, A.A, Choueiri, T.K, Hu, J.C, Kim, S.P, Kibel, A.S, Nguyen, P.L, Menon, M, Trinh, Q.-D
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Androgen Antagonists - therapeutic use
Androgen deprivation therapy
Antineoplastic Agents, Hormonal - therapeutic use
Cardiovascular Diseases - complications
Cardiovascular Diseases - mortality
Cause of Death - trends
Comorbidity
Competing-risks
Follow-Up Studies
Hematology, Oncology and Palliative Medicine
Humans
Male
Other-cause mortality
Prospective Studies
Prostate cancer
Prostatectomy - methods
Prostatic Neoplasms - complications
Prostatic Neoplasms - therapy
Registries
Risk Assessment - methods
Risk Factors
SEER Program
Surgery
Survival Rate - trends
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Purpose To examine the potential relationship between androgen deprivation therapy and other-cause mortality (OCM) in patients with prostate cancer treated with medical primary-androgen deprivation therapy, prostatectomy, or radiation. Methods A total of 137,524 patients with non-metastatic PCa treated between 1995 and 2009 within the Surveillance Epidemiology and End Results Medicare-linked database were included. Cox-regression analysis tested the association of ADT with OCM. A 40-item comorbidity score was used for adjustment. Results Overall, 9.3% of patients harbored stage III–IV disease, and 57.7% of patients received ADT. The mean duration of ADT exposure was 22.9 months (median: 9.1; IQR: 2.8–31.5). Mean and median follow-up were 66.9, and 60.4 months, respectively. At 10 years, overall-OCM rate was 36.5%; it was 30.6% in patients treated without ADT vs. 40.1% in patients treated with ADT (p 
ISSN:0748-7983
1532-2157
DOI:10.1016/j.ejso.2015.06.011